The company
Rapport Therapeutics, Inc.
RAPP · Nasdaq
RAPP stood above a rising 150-day average in 48 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 28.0% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 4
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $92.6M
- Officials’ trades on record
- 0
- Institutions holding
- 156 (+18)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 48 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Abraham CeesayChief Executive Officer | sold | 1,147at $30.66 | 7 Oct 2026filed 8 Oct 2026 |
| Abraham CeesayChief Executive Officer | sold | 3,375at $32.03 | 6 Oct 2026filed 8 Oct 2026 |
| Cheryl GaultChief Operating Officer | sold | 7,925at $33.04 | 30 Sep 2026filed 1 Oct 2026 |
| Cheryl GaultChief Operating Officer | sold | 2,075at $33.76 | 30 Sep 2026filed 1 Oct 2026 |
| Abraham CeesayChief Executive Officer | sold | 1,952at $39.05 | 23 Sep 2026filed 24 Sep 2026 |
| Abraham CeesayChief Executive Officer | sold | 215at $39.86 | 23 Sep 2026filed 24 Sep 2026 |
| Abraham CeesayChief Executive Officer | sold | 43at $41.05 | 23 Sep 2026filed 24 Sep 2026 |
| Abraham CeesayChief Executive Officer | sold | 7,141at $45.56 | 8 Sep 2026filed 9 Sep 2026 |
| Abraham CeesayChief Executive Officer | sold | 1,069at $46.01 | 8 Sep 2026filed 9 Sep 2026 |
| Krishnaswamy YeleswaramChief Development Officer | sold | 20,799at $50.31 | 25 Aug 2026filed 26 Aug 2026 |
| Krishnaswamy YeleswaramChief Development Officer | sold | 16,201at $51.06 | 25 Aug 2026filed 26 Aug 2026 |
| Abraham CeesayChief Executive Officer | sold | 18,921at $49.57 | 25 Aug 2026filed 26 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 7,172,894$298.9M | +3,955+0.1% |
| TRV GP V, LLCreduced · filed 10 Aug 2026 | 6,280,525$261.7M | -854,708−12.0% |
| ARCH Venture Management, LLCunchanged · filed 14 Aug 2026 | 3,728,738$155.4M | 00.0% |
| Capital International Investorsreduced · filed 12 Aug 2026 | 2,921,958$121.8M | -176,015−5.7% |
| GOLDMAN SACHS GROUP INCreduced · filed 14 Aug 2026 | 2,910,449$121.3M | -31,802−1.1% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 2,699,786$112.5M | +193,831+7.7% |
| Cormorant Asset Management, LPreduced · filed 14 Aug 2026 | 2,657,521$110.7M | -300,000−10.1% |
| Sofinnova Investments, Inc.unchanged · filed 14 Aug 2026 | 1,904,408$79.4M | 00.0% |
| JOHNSON & JOHNSONunchanged · filed 6 Aug 2026 | 1,784,517$74.4M | 00.0% |
| Polar Capital Holdings Plcreduced · filed 14 Aug 2026 | 1,608,514$67.0M | -33,947−2.1% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.